btlines

GRZ NewConnect Periodic report · PAP Biznes

GREEN Zebras SA (GRZ) · Q2 2026 results

Share price: 9.15 zł · 2026-11-10

Results Q2 2026 vs Q2 2024 · year over year · published 11 Aug 2026 and 12 Aug 2024

Net loss widened year on year. The language turned more upbeat.

Only a basic analysis is available for this company at the moment.

1 · Numbers

Loss widened

Net income vs Q2 2024

Net income -748.5K vs -457.0K

Revenue −0.4%

2 · How the report reads

More upbeat

Language tone vs last period

Report language: very upbeat for a company report — more upbeat than in Q2 2024.

Weak signal: formal report language, not a call.

3 · What stood out

Key theme

The issuer's share capital amounted to 158,656.80 PLN and was fully paid, confirming the company's capital structure.

Read between the lines

No major shifts flagged this period.

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q2 2024.

Report language Very upbeat (was upbeat)

Very upbeat for a company report — more upbeat than in Q2 2024. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Sentences that drove the tone
“This means the development of research and development projects without possessing own laboratory and production facilities, while simultaneously focusing activities on project management, development strategy, and the creation and development of intellectual property assets.”

Full figures

PLN · PAP Biznes report (2026-08-11)

Metric Q2 2026 Q2 2024 Change
Revenue 17.7K 17.8K −0.4%
Operating income -747.1K -593.5K Loss widened
Net income -748.5K -457.0K Loss widened
EPS -0.74 -0.34 Loss widened
P/E — — —

Topics

Topics are drawn from the full report text, not management commentary.

Most discussed now

  • The chronic nature of treatment, combined with the increasing willingness of caregivers to fund modern therapies, also ensures that these…
  • The Issuer, and the information regarding its activities, provide a true picture of the development, achievements, and situation of the…
  • Based on the Letter of Intent, the Issuer committed to preparing, in the first stage, a vaccine development plan, including, among other…
  • This model provides the company with high operational flexibility, access to global competencies, and the ability to effectively scale…
  • The Issuer estimates that developing the vaccine development plan will take approximately three months from the date of entering into the…

Faded since Q2 2024

  • Fading The Issuer possesses its own laboratory and production line, enabling it to fulfill customer orders for the production of products tailored…
  • Fading Capital from revaluation is generated as a result of the valuation of long-term financial assets (shares in other entities included in…
  • Fading Revenue from the sale of products, i.e., finished goods, and services is the amount due from the customer for this purpose, less the…
  • Fading At the same time, during the period under review, the Company realized financial income in the amount of

Latest announcements

Official filings, newest first.

Similar companies

Basic Materials · Chemicals
All Basic Materials companies →